Donanemab

ATC N06DX05 · 10 markets · 11 records

Donanemab 10 markets · 11 records Forms

AU 2 records · 2 strengths

17.5 mg/mLinjectionKISUNLA donanemab 350 mg/20 mL concentrated solution for intravenous infusion vial unknown

Records without a stated strength · 1 Kisunla

US 1 records · 1 strengths

17.5 mginjectionKisunla

GB 1 records · 1 strengths

350 mg/20 mLinjectionKisunla 350mg/20ml concentrate for solution for infusion vials also in SG·CN·TW

CA 1 records · 1 strengths

17.5 mgliquidKisunla

SG 1 records · 1 strengths

350 mg/20 mLinjectionLormalzi Concentrate for Solution for Infusion 350mg/20mL also in GB·CN·TW

CN 1 records · 1 strengths

350 mg/20 mLinjection记能达多奈单抗 also in GB·SG·TW

MX 1 records · 1 strengths

Records without a stated strength · 1 Kisunla

TW 1 records · 1 strengths

350 mg/20 mLinjectionKisunla+1欣智樂注射劑 350毫克/20毫升 also in GB·SG·CN

HK 1 records · 1 strengths

Records without a stated strength · 1 KISUNLA CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/20ML

EU 1 records · 1 strengths

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

Records without a stated strength · 1 Kisunla

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.